These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22437814)

  • 1. Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment.
    Lipscomb JC; Haddad S; Poet T; Krishnan K
    Adv Exp Med Biol; 2012; 745():76-95. PubMed ID: 22437814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic modeling for nanoparticle toxicity study.
    Li M; Reineke J
    Methods Mol Biol; 2012; 926():369-82. PubMed ID: 22975976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    Yoon M; Kedderis GL; Yan GZ; Clewell HJ
    Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Have physiologically-based pharmacokinetic models delivered?
    Edginton AN; Joshi G
    Expert Opin Drug Metab Toxicol; 2011 Aug; 7(8):929-34. PubMed ID: 21762039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation.
    Ellison CA
    Regul Toxicol Pharmacol; 2018 Nov; 99():61-77. PubMed ID: 30201539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment.
    Kedderis GL; Lipscomb JC
    Toxicol Ind Health; 2001 Jun; 17(5-10):315-21. PubMed ID: 12539878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results.
    Yoon M; Campbell JL; Andersen ME; Clewell HJ
    Crit Rev Toxicol; 2012 Sep; 42(8):633-52. PubMed ID: 22667820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative in vitro to in vivo extrapolation of tissues toxicity.
    Hamon J; Renner M; Jamei M; Lukas A; Kopp-Schneider A; Bois FY
    Toxicol In Vitro; 2015 Dec; 30(1 Pt A):203-16. PubMed ID: 25678044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: The case of kidney toxicity induced by aristolochic acid I.
    Abdullah R; Alhusainy W; Woutersen J; Rietjens IM; Punt A
    Food Chem Toxicol; 2016 Jun; 92():104-16. PubMed ID: 27016491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.
    Thiel C; Cordes H; Conde I; Castell JV; Blank LM; Kuepfer L
    Arch Toxicol; 2017 Feb; 91(2):865-883. PubMed ID: 27161439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.
    Andersen ME
    Toxicol Lett; 1995 Sep; 79(1-3):35-44. PubMed ID: 7570672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicokinetic modeling and its applications in chemical risk assessment.
    Andersen ME
    Toxicol Lett; 2003 Feb; 138(1-2):9-27. PubMed ID: 12559690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs.
    Munir A; Azam S; Fazal S; Bhatti AI
    J Theor Biol; 2018 Aug; 451():1-9. PubMed ID: 29704489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
    Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.